Table 2.
Subgroup analyses for GPC3 on HCC overall survival
| No. of studies | Effect model | HR (95% CI) | P value | Heterogeneity test | ||
|---|---|---|---|---|---|---|
| I2 (%) | P value | |||||
| Overall Sample size | 14 | Random | 1.62 (1.26–2.30) | 0.03 | 69.1 | 0.001 |
| ≤ 200 | 10 | Random | 1.49 (1.32–2.21) | 0.019 | 63.4 | 0.021 |
| > 200 | 4 | Random | 1.33 (0.76–1.68) | 0.814 | 53.7 | 0.125 |
| Duration of follow-up | ||||||
| ≤ 60 months | 6 | Fixed | 1.73 (1.42–2.67) | 0.001 | 41.5 | 0.12 |
| > 60 months | 6 | Random | 1.54 (0.57–1.69) | 0.196 | 70.2 | 0.001 |
| Cut-off value | ||||||
| 5% | 1 | – | 0.60 (0.33–1.29) | 0.071 | – | – |
| 10% | 8 | Random | 1.29 (0.86–2.10) | 0.81 | 71.4 | 0.008 |
| 20% | 4 | Fixed | 1.48 (0.71–2.67) | 0.176 | 0 | 0.601 |
| 25% | 1 | – | 2.14 (1.21–3.43) | 0.002 | – | – |
Subgroup analyses for the association between GPC3 and OS, based on sample size, follow-up period, and cut-offs, were conducted in this table